These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 22076471)
1. Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design. Schaefer B; Kisker C; Sotriffer CA J Comput Aided Mol Des; 2011 Nov; 25(11):1053-69. PubMed ID: 22076471 [TBL] [Abstract][Full Text] [Related]
2. In Silico Drug Design of Thiolactomycin Derivatives Against Mtb-KasA Enzyme to Inhibit Multidrug Resistance of Mycobacterium tuberculosis. Durairaj DR; Shanmughavel P Interdiscip Sci; 2019 Jun; 11(2):215-225. PubMed ID: 28856604 [TBL] [Abstract][Full Text] [Related]
3. Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB. Schaeffer ML; Agnihotri G; Volker C; Kallender H; Brennan PJ; Lonsdale JT J Biol Chem; 2001 Dec; 276(50):47029-37. PubMed ID: 11600501 [TBL] [Abstract][Full Text] [Related]
5. Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. Luckner SR; Machutta CA; Tonge PJ; Kisker C Structure; 2009 Jul; 17(7):1004-13. PubMed ID: 19604480 [TBL] [Abstract][Full Text] [Related]
6. A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA. Inoyama D; Awasthi D; Capodagli GC; Tsotetsi K; Sukheja P; Zimmerman M; Li SG; Jadhav R; Russo R; Wang X; Grady C; Richmann T; Shrestha R; Li L; Ahn YM; Ho Liang HP; Mina M; Park S; Perlin DS; Connell N; Dartois V; Alland D; Neiditch MB; Kumar P; Freundlich JS Cell Chem Biol; 2020 May; 27(5):560-570.e10. PubMed ID: 32197094 [TBL] [Abstract][Full Text] [Related]
7. Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA. Kumar P; Capodagli GC; Awasthi D; Shrestha R; Maharaja K; Sukheja P; Li SG; Inoyama D; Zimmerman M; Ho Liang HP; Sarathy J; Mina M; Rasic G; Russo R; Perryman AL; Richmann T; Gupta A; Singleton E; Verma S; Husain S; Soteropoulos P; Wang Z; Morris R; Porter G; Agnihotri G; Salgame P; Ekins S; Rhee KY; Connell N; Dartois V; Neiditch MB; Freundlich JS; Alland D mBio; 2018 Dec; 9(6):. PubMed ID: 30563908 [TBL] [Abstract][Full Text] [Related]
8. Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design. Lee W; Luckner SR; Kisker C; Tonge PJ; Engels B Biochemistry; 2011 Jun; 50(25):5743-56. PubMed ID: 21615093 [TBL] [Abstract][Full Text] [Related]
9. Structural insight into conformational dynamics of non-active site mutations in KasA: A Mycobacterium tuberculosis target protein. Jayaraman M; Rajendra SK; Ramadas K Gene; 2019 Dec; 720():144082. PubMed ID: 31476406 [TBL] [Abstract][Full Text] [Related]
10. X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB). Sridharan S; Wang L; Brown AK; Dover LG; Kremer L; Besra GS; Sacchettini JC J Mol Biol; 2007 Feb; 366(2):469-80. PubMed ID: 17174327 [TBL] [Abstract][Full Text] [Related]
11. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Slayden RA; Lee RE; Barry CE Mol Microbiol; 2000 Nov; 38(3):514-25. PubMed ID: 11069675 [TBL] [Abstract][Full Text] [Related]